Juridical Foundation the Chemo-sero-therapeutic Research Institute

Isis Pharmaceuticals, Inc.

501 Juridical Foundation, the Chemo-sero-therapeutic Research Institute

Fukusaburo Hamada

Chikateru Nozaki

Nobuya Ohtomo

Kevin P Anderson

Ronnie C Hanecak

Masashi Sakaguchi

Hiroshi Nakatake

Tsukasa Nishihara

Tatsuo Eto

Shinichi Furukawa

Kazuo Matsuo

Keishin Sugahara

Kazuya Hoshiko

Thomas W Bruice

Walter F Lima

Sachio Tokiyoshi

Hiroshi Mizokami

Eiji Tokunaga

Atsushi Miyanohara

Kenichi Matsubara

Shoji Furusako

Takayuki Imamura

Kyosuke Mizuno

Satoshi Adachi

Akio Toh-e

Shoji Furasako

Kengo Sonoda

Fumio Miake

Kou-ichi Shiosaki

Haruo Fujita

Kazuhide Yagami

A novel peptide obtained fromhas been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.

Polypeptide for Haemophilus paragallinarum and process for preparing the same

A novel peptide obtained from has been found useful for preventing avian infectious coryza. This polypeptide induces production of hemagglutination-inhibition antibody and prevents infection and onset of avian infectious coryza. The invention further provides a gene coding for the polypeptide, a recombinant vector for expression of this gene, a host transformed with this vector, a process for preparing the polypeptide in a host, a vaccine for avian infectious coryza comprising the polypeptide as an active ingredient, a monoclonal antibody obtained using the polypeptide as an immunogen, and a diagnostic agent and a therapeutic agent for avian infectious coryza using the peptide and the antibody.

Polypeptide originating in haemophilus paragallinarum and process for producing the same

Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

Compositions and methods for treatment of Hepatitis C virus-associated diseases

Compositions and methods for treatment of hepatitis C virus-associated diseases

Recombinant Marek's disease virus (MDV) and vaccine

A recombinant DNA comprising 3 fragments of Hepatitis B virus DNA recombined with a vector consisting essentially of 0.31 Kb replication orgin of SV40 DNA inserted into EcoRI cleavage site of Escherichia coli plasmid which is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells, wherein each HBV DNA fragment is a 3.2 Kb BamHI fragment consisting of 1.9 Kb HBc gene and 1.3 Kb HBs gene, and said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail, mammalian cells transformed with the recombinant DNA, and a method of production of Hepatitis B virus proteins, i.e. HBsAg and/or HBeAg. These HBV proteins have the same immunological properties as those of the natural HBV proteins originated from human blood plasma and can be used for the preparation of HBV vaccine and diagnostic reagents.

Recombinant DNA inserted with hepatitis B virus gene, mammalian cells

Shuttle vectors including a DNA sequence of the yeast Saccharomyces cerevisiae including ars 1.2 micron ori and a marker gene for transformed yeast permitting synthesis of leucine by the transformant; adjacent to said ars 1 a DNA sequence of Escherichia coli which is either in EcoR1--PvuII or EcoR1--TthIII--I fragment of plasmid pBR322; and adjacent to the yeast marker gene the expression control region of the repressible acid phosphatase gene of yeast.

Yeast shuttle vector

A method for the purification of HBc antigen, particularly HBc antigen produced by recombinant organisms by means of DNA recombination technique, which comprises subjecting a solution containing HBc antigen to acid-treatment, wherein the solution containing HBc antigen is acidified to a pH range of not higher than 6 by adding an acid and then resulting precipitates of lipid and contaminant proteins are removed, and then subjecting the acid-treated solution containing HBc antigen to an ion exchange chromatography with an anion exchanger, and a method for measuring HBc antibody by using said purified HBc antigen in a passive hemagglutination method, EIA method or RIA method.

Method for purification of HBc antigen and method for measurement of HBc

A recombinant plasmid inserted with Hepatitis B virus gene, which comprises a plasmid vector containing a yeast gene and an E. coli gene and carrying the expression control region of the repressible acid phosphatase gene of yeast and a Hepatitis B virus gene recombined thereto under control of the phosphatase promoter, a transformed yeast which is prepared by transforming a yeast with the recombinant plasmid, and a method of the production of Hepatitis B virus surface antigen in a large scale by culturing the transformed yeast in a medium. The Hepatitis B virus surface antigen prepared by the present invention has the same immunological properties as those of the natural antigen from human blood plasma and is useful for the preparation of Hepatitis B virus vaccine and diagnostic reagents.

Recombinant plasmid inserted with hepatitis B virus gene, yeast

Industrially useful method for the purification of HBs antigen produced by a recombinant organism being capable of producing HBs antigen which is prepared by means of DNA recombination technique, which comprises subjecting an HBs antigen-containing material produced by a recombinant organism to an adsorption chromatography with a silica, optionally followed by a gel filtration and further an adsorption chromatography with a hydroxyapatite, and then eluting the HBs antigen, preferably, with a buffer having a pH 9 or more which is incorporated with urea. The purification method can give a highly pure HBs antigen suitable for the preparation of hepatitis B vaccine in a large scale from recombinant organisms prepared by DNA recombination technique.

Method for purification of HBs antigen

Lyophilized preparation of hepartitis B vaccine, which comprises a purified hepatitis B virus surface antigen produced by a recombinant organism being capable of producing HBs antigen, which is adsorbed on aluminum gel in the lyophilized state in the presence of a stabilizer, said lyophilized preparation being prepared by the steps of adding an aluminum gel and a stabilizer to a purified recombinant-origin HBs antigen and lyophilizing the mixture. Said lyophilized preparation being able to be stably kept for a long period of time without losing its antigen titer and being useful for the prophylaxis of infection of hepatitis B virus.

Lyophilized hepatitis B vaccine

A method for purification of HBs antigen, which comprises treating an HBs tigen-containing material with an acid, optionally subjecting to salting out with ammonium sulfate, and subjecting the material to a chromatography with hydroxyapatite, by which a highly purified HBs antigen suitable for the preparation of HBV vaccine or diagnostic agent can be obtained in an industrial scale. This method is particularly useful for the purification of HBs antigen-containing material produced by recombinants obtained by DNA recombination technique.

Growing community of inventors

Nishigoshi-machi, Japan

Fukusaburo Hamada